PMID- 37751990
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20240210
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Print)
IS  - 1930-7381 (Linking)
VI  - 31
IP  - 11
DP  - 2023 Nov
TI  - Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, 
      placebo-controlled trial.
PG  - 2762-2773
LID - 10.1002/oby.23898 [doi]
AB  - OBJECTIVE: Binge-eating disorder (BED) is a prevalent psychiatric disorder 
      associated with obesity. Few evidence-based treatments exist for BED, 
      particularly pharmacological options. This study tested the efficacy of 
      naltrexone/bupropion for BED. METHODS: A randomized, double-blind, 
      placebo-controlled, 12-week trial tested naltrexone/bupropion for BED with and 
      without obesity. Eighty-nine patients (70.8% women, 69.7% White, mean age 45.7 y, 
      mean BMI 35.1 kg/m(2) , 77.5% with BMI >/= 30 kg/m(2) ) were randomized to placebo 
      (n = 46) or naltrexone/bupropion (n = 43), with randomization stratified by 
      obesity status and gender; 92.1% completed post-treatment assessments. RESULTS: 
      Mixed models of binge-eating frequency revealed significant reductions that did 
      not differ significantly between naltrexone/bupropion and placebo. Logistic 
      regression of binge-eating remission rates revealed that naltrexone/bupropion and 
      placebo did not differ significantly. Obesity status did not predict, or 
      moderate, binge-eating outcomes considered either continuously or categorically. 
      Mixed models revealed that naltrexone/bupropion was associated with significantly 
      greater percentage weight loss than placebo. Logistic regression revealed that 
      naltrexone/bupropion had significantly higher rates of attaining >/=5% weight loss 
      than placebo (27.9% vs. 6.5%). Obesity status did not predict or moderate 
      weight-loss outcomes. CONCLUSIONS: Naltrexone/bupropion did not demonstrate 
      effectiveness for reducing binge eating relative to placebo but showed 
      effectiveness for weight reduction in patients with BED. Obesity status did not 
      predict or moderate medication outcomes.
CI  - (c) 2023 The Obesity Society.
FAU - Grilo, Carlos M
AU  - Grilo CM
AUID- ORCID: 0000-0003-0245-3444
AD  - Department of Psychiatry, Yale University School of Medicine, New Haven, 
      Connecticut, USA.
FAU - Lydecker, Janet A
AU  - Lydecker JA
AUID- ORCID: 0000-0001-6425-514X
AD  - Department of Psychiatry, Yale University School of Medicine, New Haven, 
      Connecticut, USA.
FAU - Jastreboff, Ania M
AU  - Jastreboff AM
AUID- ORCID: 0000-0003-1446-0991
AD  - Department of Medicine (Endocrinology and Metabolism), Yale University School of 
      Medicine, New Haven, Connecticut, USA.
FAU - Pittman, Brian
AU  - Pittman B
AD  - Department of Psychiatry, Yale University School of Medicine, New Haven, 
      Connecticut, USA.
FAU - McKee, Sherry A
AU  - McKee SA
AD  - Department of Psychiatry, Yale University School of Medicine, New Haven, 
      Connecticut, USA.
LA  - eng
GR  - K23 DK115893/DK/NIDDK NIH HHS/United States
GR  - R01 DK112771/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20230926
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 01ZG3TPX31 (Bupropion)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Male
MH  - Bupropion/therapeutic use
MH  - Naltrexone/therapeutic use
MH  - *Binge-Eating Disorder/complications
MH  - Obesity/therapy
MH  - *Bulimia/complications
MH  - Weight Loss
MH  - Double-Blind Method
MH  - Treatment Outcome
PMC - PMC10600891
MID - NIHMS1938836
COIS- Potential Conflicts of interest: The authors declare no conflicts of interest 
      relative to this study. Dr. Grilo reports broader interests, which did not 
      influence this research, including Honoraria for lectures, and Royalties from 
      Guilford Press and Taylor & Francis Publishers for academic books. Dr. Jastreboff 
      reports broader interests, which did not influence this study, including serving 
      on Scientific Advisory Boards for to Amgen, AstraZeneca, BioHaven 
      Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, Intellihealth, Novo 
      Nordisk, , Pfizer, Rhythm Pharmaceuticals, Scholar Rock, Structure Therapeutics, 
      Terns Pharmaceuticals, Weight Watchers International, and Zealand Pharma A/S.
EDAT- 2023/09/27 00:42
MHDA- 2023/10/23 01:18
PMCR- 2024/11/01
CRDT- 2023/09/26 21:22
PHST- 2023/08/01 00:00 [revised]
PHST- 2023/05/25 00:00 [received]
PHST- 2023/08/04 00:00 [accepted]
PHST- 2024/11/01 00:00 [pmc-release]
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/09/27 00:42 [pubmed]
PHST- 2023/09/26 21:22 [entrez]
AID - 10.1002/oby.23898 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2023 Nov;31(11):2762-2773. doi: 10.1002/oby.23898. Epub 
      2023 Sep 26.